Fiducial Markers Market Size, Trends, In-depth Analysis, Regional Revenue, Forecast To 2026

By Author: robert henric
Total Articles: 492
Comment this article

The Research Report on “Fiducial Markers Market by Product (Metal Based Markers (Gold, Gold Combination) Polymer Markers), Cancer Type (Prostate, Lung, Breast), Modality (CT, CBCT, MRI, Ultrasound), End user (Hospitals, Outpatient Facilities) – Global Forecast to 2025″, is projected to reach USD 123 million by 2025 from USD 95 million in 2019, at a CAGR of 4.5% from 2019 to 2025.

Recent Developments:

In 2019, Stratpharma AG (Switzerland) expanded its agreement with CIVCO (US) to distribute CIVCO’s radiotherapy solutions globally
In 2019, IZI Medical Products (US) acquired the RadioMed division of IBA (Belgium), which manufactures the VISICOIL implantable fiducial markers
In 2018, Nanovi A/S (Denmark) secured USD 2.23 million from existing investors to expand its business and introduce BioXmark in the European market
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=180673710

Industry Segmentation In Detailed:

The metal-based FMs product segment to register significant growth over the forecast period

Based on product, the fiducial markers ...
... market is classified into metal-based markers, polymer-based markers, and others. The metal-based markers segment is expected to register significant growth over the forecast period of 2019 to 2025. The adoption of radiotherapy has increased in recent years due to its advantages, such as high precision & radiation control, reduced risk of side-effects, and minimal exposure of healthy tissues to radiation. As metal-based FMs are widely preferred for tumor localization, the rising adoption of radiotherapy procedures is expected to support market growth.

The CT/CBCT modality segment is projected to hold the largest share of the market during the forecast period of 2019 to 2025

On the basis of modality, the fiducial markers market is classified into CT/CBCT, MRI, ultrasound, and radiotherapy. CBCT is preferred for prostate and lung cancer indications, as it effectively detects changes in the position of cancer tumors. Thus, the rising incidences of prostate & lung cancer and the widespread use of CBCT in most developed countries for cancer diagnosis and treatment are the key factors driving the segment growth.

Prostate cancer segment to grow at the highest CAGR over the forecast period

Based on cancer type, the fiducial markers market is broadly segmented into prostate cancer, lung cancer, breast cancer, gastric cancer, and others. Among these, the prostate cancer segment is anticipated to register significant growth over the forecast period due to the rising incidences of prostate cancer globally and the high cure rate associated with radiotherapy. For instance, according to a study published in the Journal of Medical Imaging and Radiation Oncology, the use of EBRT in men suffering from prostate cancer showed a cure rate of ~95.5% for intermediate-risk prostate cancer.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=180673710

Leading Key Players and Analysis:

The major players in the market include CIVCO Radiotherapy (US), IZI Medical Products (US), Boston Scientific Corporation (US), Naslund Medical AB (Sweden), and IBA (Belgium). Other players are Best Medical International, Inc. (US), Nanovi A/S (Denmark), Carbon Medical Technologies (US), Eckert & Ziegler (Germany), Innovative Oncology Solutions (US), Medtronic (Ireland), and QFIX (US).

CIVCO Radiotherapy (US) dominated t­he global fiducial markers market in 2019. Its strong product portfolio and high geographic penetration are the ­key factors contributing to the leading position of this company in the market. In order to maintain its dominant position, the company develops both metal-based as well as polymer-based fiducial markers, such as FusionCoil, PolyMark, FlexiCoil, Align, and PointCoil. The company is also focusing on increasing its presence in developing countries to leverage high-growth opportunities.

Boston Scientific (US) held the second-largest market position in the global judicial markers industry. It became a key player in the market after the launch of its LumiCoil platinum fiducial marker. The company’s strong R&D capabilities and global manufacturing & distribution network are its major strengths.

Geographical Analysis in Detailed:

The fiducial markers market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America is projected to hold the largest share of the regional market for fiducial markers in 2019. This is attributed to the expansion of the target patient population, favorable reimbursement scenario, greater accessibility to radiotherapy procedures, and the presence of major players in this region.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=180673710